Orthobiologic Subchondroplasty is a minimally invasive procedure that involves injecting a bone substitute material that is combined with bone marrow concentrate injections into the subchondral bone, which is located just beneath the cartilage.
Orthobiologic Subchondroplasty is designed to repair defects in the bone and promote the growth of healthy tissue, which can help alleviate pain and improve joint function. In this article, we will explore the definition and function of Orthobiologic Subchondroplasty, the appropriate candidates and procedure for the treatment, as well as the risks and recovery time involved.
Orthobiologic Subchondroplasty (OSP) is a minimally invasive surgical technique used to treat chronic bone marrow lesions (BMLs) in the subchondral bone. According to McWilliams et al. (2020), OSP involves the injection of a calcium phosphate bone substitute into the subchondral bone, where it hardens and provides structural support to the bone. OSP is intended to repair the subchondral bone and provide pain relief by stabilizing the joint and preventing further damage to the articular cartilage. The use of OSP has been shown to be effective in the treatment of chronic BMLs in the foot and ankle, resulting in significant improvement in pain and function in patients. OSP can also be used in conjunction with other orthobiologic treatments, such as platelet-rich plasma (PRP) therapy and bone marrow aspirate concentrate (BMAC) therapy, to provide a more comprehensive approach to joint repair. Overall, OSP is a promising technique for the treatment of chronic BMLs and has the potential to improve patient outcomes and quality of life.
Orthobiologic Subchondroplasty (OSP) is a promising treatment option for patients with subchondral bone marrow lesions (BMLs) and early osteoarthritis (OA). However, not all patients are appropriate candidates for this procedure. HA Oliver et al. (2020) stated that patients with larger BMLs, advanced OA, or significant joint malalignment may not benefit as much from OSP as those with smaller BMLs and less severe OA. Proper patient selection is crucial to achieving optimal outcomes with OSP. In addition to patient selection, the OSP procedure itself must be performed with precision and accuracy. According to Oliver et al. (2020), the key steps of OSP include accurate preoperative planning, precise intraoperative fluoroscopic guidance, and careful injection of the bone graft material. Failure to perform these steps correctly can lead to suboptimal outcomes and potential complications. With appropriate patient selection and proper procedure execution, OSP can offer significant pain relief and functional improvement for patients with subchondral BMLs and early OA.
Orthobiologic subchondroplasty (OSP) is an emerging technique for the management of subchondral bone defects. It involves the injection of a composite material comprised of calcium phosphate and bone marrow aspirate into the subchondral bone of the joint. This technique has shown promising results in the treatment of various orthopedic conditions such as osteoarthritis, osteochondritis dissecans, and avascular necrosis. However, like any other medical procedure, OSP is associated with certain risks. One of the major risks of OSP is the potential for intraoperative fracture. According to Cohen and Sharkey (2016), “the risk of intraoperative fracture is higher in patients with advanced osteoarthritis and subchondral cysts” (p. 1186). Another risk associated with OSP is the possibility of infection. Although the risk of infection is low, it is still a concern. In terms of recovery time, patients who undergo OSP typically experience a shorter recovery time than those who undergo traditional surgery. According to Cohen and Sharkey (2016), “recovery time after OSP is generally quicker than that after osteotomy or joint replacement” (p. 1187). However, the recovery time may vary depending on the extent of the procedure and the patient’s overall health. In conclusion, OSP is a promising technique for the management of subchondral bone defects. While it does carry certain risks, the potential benefits such as faster recovery time make it a viable option for patients with orthopedic conditions.
In conclusion, Orthobiologic Subchondroplasty is a minimally invasive procedure that is used to treat bone defects and chronic pain in individuals who have osteoarthritis or other joint conditions. During the procedure, an orthopedic surgeon injects a bone substitute material into the damaged area to stimulate bone growth and reduce pain. This procedure is ideal for patients who have not experienced relief from other conservative treatments. While the risks of complications are relatively low, possible complications may include infection or nerve damage. Recovery time may vary depending on the individual and their condition, but most patients can expect to return to their normal activities within a few weeks to a few months. Overall, Orthobiologic Subchondroplasty can be an effective and safe option for those suffering from chronic joint pain and bone defects.
Research
- L Yao.”Subchondroplasty of the ankle and hindfoot for treatment of osteochondral lesions and stress fractures: initial imaging experience.” https://journals.sagepub.com/doi/pdf/10.1177/1938640019863252
- “Subchondroplasty for treating bone marrow lesions.” https://www.thieme-connect.com/products/ejournals/html/10.1055/s-0035-1568988
- “Enhanced subchondroplasty treatment for post‐traumatic cartilage and subchondral bone marrow lesions in a canine model.” https://onlinelibrary.wiley.com/doi/abs/10.1002/jor.24508